Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy.

Adult Area Under Curve Carbamates / adverse effects Female Furans / adverse effects HIV Infections / drug therapy HIV Protease Inhibitors / adverse effects Humans Maternal Age Pregnancy Pregnancy Complications, Infectious / drug therapy Pregnancy Trimesters RNA, Viral / blood Ritonavir / adverse effects Sulfonamides / adverse effects Viral Load
AIDS amprenavir fosamprenavir human immunodeficiency virus pharmacokinetics postpartum pregnancy ritonavir

Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
24 03 2020
Historique:
received: 10 11 2019
accepted: 07 01 2020
pubmed: 6 2 2020
medline: 23 2 2021
entrez: 5 2 2020
Statut: epublish

Résumé

The purpose of this study was to evaluate the pharmacokinetics of ritonavir-boosted fosamprenavir during pregnancy and postpartum. Amprenavir (the active moiety of fosamprenavir) and ritonavir intensive pharmacokinetic evaluations were performed at steady state during the second and third trimesters of pregnancy and postpartum. Plasma concentrations of amprenavir and ritonavir were measured using high-performance liquid chromatography. The target amprenavir area under the concentration-versus-time curve (AUC) was higher than the 10th percentile (27.7 μg · h/ml) of the median area under the curve for ritonavir-boosted fosamprenavir in adults receiving twice-daily fosamprenavir-ritonavir at 700 mg/100 mg. Twenty-nine women were included in the analysis. The amprenavir AUC from time zero to 12 h (AUC

Identifiants

DOI: 10.1128/AAC.02260-19 PMID: 32015036 PMC: PMC7179299
pubmed: 32015036
pii: AAC.02260-19
doi: 10.1128/AAC.02260-19
pmc: PMC7179299
pii:
doi:

Substances chimiques

Carbamates 0
Furans 0
HIV Protease Inhibitors 0
RNA, Viral 0
Sulfonamides 0
Ritonavir O3J8G9O825
fosamprenavir WOU1621EEG

Types de publication

Clinical Trial Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : UM1 AI068616
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068632
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI106716
Pays : United States

Investigateurs

Linda Bettica (L)
Charmane Calilap-Bernardo (C)
Arlene Bardeguez (A)
Shelley Buschur (S)
Chivon Jackson (C)
Mary Paul (M)
Philip La Russa (P)
Claudia Florez (C)
Patricia Bryan (P)
Monica Stone (M)
Debra McLaud (D)
Christina Yarrington (C)
Diana Clarke (D)
Nagamah Deygoo (N)
William Borkowsky (W)
Françoise Kamer (F)
LaShonda Spencer (L)
James Homans (J)
Esau C Joao (EC)
Camille Medeiros Braga (CM)
Marcelo H Losso (MH)
Silvina A Ivalo (SA)
Alejandro Hakim (A)
Julie Schmidt (J)
Maureen McNichols (M)
Mariam Aziz (M)
Jaime G Deville (JG)
Karin Nielsen (K)
Bonnie Ank (B)
Katherine M Knapp (KM)
Nina Sublette (N)
Edwin Thorpe (E)

Informations de copyright

Copyright © 2020 American Society for Microbiology.

Références

Semin Perinatol. 2015 Nov;39(7):512-9
pubmed: 26452316
CPT Pharmacometrics Syst Pharmacol. 2018 Feb;7(2):103-110
pubmed: 29349870
J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):412-9
pubmed: 21283017
Viruses. 2017 Sep 28;9(10):
pubmed: 28956865
Ann Pharmacother. 2002 Jan;36(1):102-18
pubmed: 11816239
Antimicrob Agents Chemother. 2001 Jan;45(1):30-7
pubmed: 11120940
J Antimicrob Chemother. 2012 Feb;67(2):299-311
pubmed: 22160207
Drugs. 2004;64(18):2101-24
pubmed: 15341507
J Antimicrob Chemother. 2007 Feb;59(2):238-45
pubmed: 17202245
Ther Drug Monit. 2011 Dec;33(6):772-7
pubmed: 22105596
J Antimicrob Chemother. 2007 Nov;60(5):987-93
pubmed: 17890284
N Engl J Med. 2019 Apr 4;380(14):1293-1295
pubmed: 30943333
J Clin Pharmacol. 2019 Mar;59(3):386-393
pubmed: 30358179
Antimicrob Agents Chemother. 2003 Jan;47(1):118-23
pubmed: 12499178
Drugs. 2000 Dec;60(6):1383-410
pubmed: 11152018
Drug Metab Dispos. 2013 Feb;41(2):256-62
pubmed: 23328895
Antivir Ther. 2008;13(8):1039-46
pubmed: 19195329
J Clin Pharmacol. 2019 Jun;59(6):779-783
pubmed: 30821843
AIDS. 2006 Oct 3;20(15):1931-9
pubmed: 16988514
Am J Obstet Gynecol. 2005 Feb;192(2):633-9
pubmed: 15696014
Int J Oncol. 2017 Mar;50(3):823-834
pubmed: 28197631
Antimicrob Agents Chemother. 2012 Nov;56(11):5938-45
pubmed: 22964257
J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):550-4
pubmed: 23314414
Antimicrob Agents Chemother. 2004 Mar;48(3):791-8
pubmed: 14982766
Drugs. 2005;65(5):633-59
pubmed: 15748098
Expert Opin Drug Metab Toxicol. 2010 Jun;6(6):689-99
pubmed: 20367533
Clin Pharmacokinet. 2006;45(2):137-68
pubmed: 16485915
HIV Med. 2015 Mar;16(3):176-83
pubmed: 25407158
Expert Opin Drug Metab Toxicol. 2019 Jul;15(7):523-525
pubmed: 31185758
J Acquir Immune Defic Syndr. 2010 Aug;54(4):381-8
pubmed: 20632458
Antimicrob Agents Chemother. 2006 Nov;50(11):3950-2
pubmed: 16954312
J Acquir Immune Defic Syndr. 2013 May 1;63(1):59-66
pubmed: 23392467
Clin Pharmacokinet. 2007;46(9):739-56
pubmed: 17713972
Drug Metab Dispos. 2008 Jul;36(7):1315-21
pubmed: 18420783
Antivir Ther. 2015;20(1):57-64
pubmed: 24992294
J Acquir Immune Defic Syndr. 2018 Jul 1;78(3):308-313
pubmed: 29528944

Auteurs

Ahizechukwu C Eke (AC)

Division of Maternal Fetal Medicine and Clinical Pharmacology, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA aeke2@jhu.edu.
Doctoral Training Program (PhD), Graduate Training Program in Clinical Investigation, Johns Hopkins University School of Public Health, Baltimore, Maryland, USA.
ORCID: 0000-0002-0070-9840

Jiajia Wang (J)

Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.

Khadija Amin (K)

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA.

David E Shapiro (DE)

Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.

Alice Stek (A)

Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, University of Southern California School of Medicine, Los Angeles, California, USA.

Elizabeth Smith (E)

Pediatric Medicine Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.

Nahida Chakhtoura (N)

Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, USA.

Michael Basar (M)

Frontier Science and Technology Research Foundation, Amherst, New York, USA.

Kathleen George (K)

Family Health International, Durham, North Carolina, USA.

Katherine M Knapp (KM)

Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Esaú C João (EC)

Infectious Diseases Department, Hospital dos Servidores do Estado, Rio de Janeiro, Brazil.

Kittipong Rungruengthanakit (K)

Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.

Edmund Capparelli (E)

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA.
Pediatrics Department-Rady Children's Hospital, University of California, San Diego, San Diego, California, USA.

Sandra Burchett (S)

Division of Infectious Diseases, Department of Pediatrics, Children's Hospital Boston, Boston, Massachusetts, USA.

Mark Mirochnick (M)

Division of Neonatology, Department of Pediatrics, Boston University School of Medicine, Boston, Massachusetts, USA.

Brookie M Best (BM)

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA.
Pediatrics Department-Rady Children's Hospital, University of California, San Diego, San Diego, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Fosamprenavir with Ritonavir Pharmacokinetics...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Aire sous la courbe › Fosamprenavir with Ritonavir Pharmacokinetics...
questionsmedicales.fr › Composés chimiques organiques › Acides carboxyliques › Acides acycliques › Carbamates › Fosamprenavir with Ritonavir Pharmacokinetics...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Furanes › Fosamprenavir with Ritonavir Pharmacokinetics...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Fosamprenavir with Ritonavir Pharmacokinetics...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Inhibiteurs de protéases virales › Inhibiteurs de protéase du VIH › Fosamprenavir with Ritonavir Pharmacokinetics...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Fosamprenavir with Ritonavir Pharmacokinetics...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Facteurs épidémiologiques › Facteurs âges › Âge maternel › Fosamprenavir with Ritonavir Pharmacokinetics...
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Reproduction › Grossesse › Fosamprenavir with Ritonavir Pharmacokinetics...
questionsmedicales.fr › Maladies urogénitales › Maladies de l'appareil urogénital féminin et complications de la grossesse › Complications de la grossesse › Complications infectieuses de la grossesse › Fosamprenavir with Ritonavir Pharmacokinetics...
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Trimestres de grossesse › Fosamprenavir with Ritonavir Pharmacokinetics...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN viral › Fosamprenavir with Ritonavir Pharmacokinetics...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Thiazoles › Ritonavir › Fosamprenavir with Ritonavir Pharmacokinetics...
questionsmedicales.fr › Composés chimiques organiques › Composés du soufre › Sulfones › Sulfonamides › Fosamprenavir with Ritonavir Pharmacokinetics...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Charge virale › Fosamprenavir with Ritonavir Pharmacokinetics...